{"id":"nandrolone-cyclotate","rwe":[{"pmid":"4740146","year":"1973","title":"Clinical-pharmacological investigation of the nitrogen-retaining effect of nandrolone cyclotate.","finding":"","journal":"Acta endocrinologica","studyType":"Clinical Study"}],"tags":[{"label":"Androgen","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Anabolic Agents","category":"pharmacology"},{"label":"Androgens","category":"pharmacology"},{"label":"Hormones","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"sanabolicum","offLabel":[],"synonyms":["sanabolicum","nandrolone cyclotate"],"timeline":[],"approvals":[],"brandName":"Sanabolicum","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"Androgen","explanation":"Think of androgen receptors like locks on a door. Sanabolicum is a key that fits into these locks, allowing it to influence the activity of cells that respond to androgens, such as testosterone. This can lead to changes in the body, including the development of male characteristics like muscle growth and facial hair.","oneSentence":"Sanabolicum works by binding to androgen receptors in the body, which can influence the development and maintenance of male characteristics.","technicalDetail":"Sanabolicum, as an androgen, is believed to exert its effects through agonism of the androgen receptor (AR), a nuclear receptor that plays a critical role in the regulation of gene expression involved in the development and maintenance of male characteristics."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1880","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NANDROLONE CYCLOTATE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:37:00.769397","biosimilars":[],"competitors":[],"genericName":"nandrolone cyclotate","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"MMSL":"2095","NDDF":"001259","UNII":"1MG9GW4ZH8","CHEBI":"CHEBI:135684","VANDF":"4019854","INN_ID":"295","RXNORM":"7244","UMLSCUI":"C2828223","ChEMBL_ID":"CHEMBL2104906","KEGG_DRUG":"D01476","DRUGBANK_ID":"DB13169","PUBCHEM_CID":"164526","SNOMEDCT_US":"126171003","MESH_DESCRIPTOR_UI":"D009277"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"1973 May","pmid":"4740146","title":"Clinical-pharmacological investigation of the nitrogen-retaining effect of nandrolone cyclotate.","journal":"Acta endocrinologica"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sanabolicum, also known as NANDROLONE CYCLOTATE, is an androgenic small molecule drug. Its exact target is unknown, but it is classified as an androgen, which suggests it may interact with androgen receptors. Sanabolicum's commercial status and approved indications are unclear, and it is not known whether it is FDA-approved or off-patent. As an androgen, Sanabolicum may be used to treat conditions related to hormone imbalances, but its specific uses and safety considerations are not well-documented. Further research is needed to fully understand this drug's properties and potential applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}